No Data
ImmuneOnco Biopharmaceuticals Names Chief Business Officer
IMMUNEONCO-B (01541.HK) has appointed Weihai He as the Chief Business Officer.
Gelonghui May 6丨IMMUNEONCO-B (01541.HK) announced that Weihai He has been appointed as the Chief Business Officer of the group, effective from May 5, 2025. Weihai He is based in the USA and reports directly to the company's founder, Director, CEO, and Chief Scientific Officer Tian Wenzhi.
ImmuneOnco Biopharmaceuticals (Shanghai) Reaches HK$2.9b Market Cap Benefiting Insider Stock Buying
IMMUNEONCO-B: Annual Report 2024
ImmuneOnco Biopharmaceuticals Gets Go-Ahead to List Converted H Shares in Hong Kong
IMMUNEONCO-B (01541.HK): Listed in Hong Kong has been granted listing approval by the Stock Exchange for full circulation.
Gelonghui reported on April 24 that IMMUNEONCO-B (01541.HK) announced that the company has applied to the Listing Committee of the Stock Exchange for approval to list and trade 14,114,006 shares of H shares ("Converted H Shares", the maximum number of non-listed shares that can be converted according to the filing notice) on the Main Board of the Stock Exchange. The company is pleased to announce that the Stock Exchange has granted approval for listing on April 24, 2025.
